Global expansion EvaClean has recently expanded via EU partnerships to deploy its Infection Prevention System across multiple European countries and beyond, signaling growing international sales opportunities for channel partners and distributors.

Protexus differentiation Early adoption and ongoing prominence of electrostatic spraying technology position EvaClean as a premium solution for facilities seeking reliable disinfection with reduced labor and human error, suggesting opportunities to target high-traffic, high-risk sectors.

EPA approved PurOne and PurTab disinfectants hold EPA List-N and COVID-19 fighting product status and offer biofilm efficacy, enabling targeted selling to healthcare, education, and remediation customers prioritizing compliant, effective disinfectants.

Biofilm leadership EvaClean’s achievement as the first EPA registered chemistry effective against dry surface biofilm creates a compelling value proposition for hospitals, long-term care, and industrial facilities facing stubborn biofilm challenges.

Strategic partnerships Recent collaborations with Microsplitting, The Infection Prevention Strategy, and Navy-related applications indicate a receptive partner network and potential co-sell or reseller arrangements to accelerate market penetration.